Abstract: Provided is a technique for efficiently predicting the number (quantity) of occurrences of emergency medical service requests in a target area.

Abstract: An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.

Abstract: The present invention provides: a modified FcRn-binding domain having an enhanced affinity for the Fc Receptor neonatal (FcRn) at neutral pH; an antigen-binding molecule comprising said FcRn-binding domain, which has low immunogenicity, high stability and form only a few aggregates; a modified antigen-binding molecule having an increased FcRn-binding activity at neutral or acidic pH without an increased binding activity at neutral pH for a pre-existing anti-drug antibody; use of the antigen-binding molecules for improving antigen-binding molecule-mediated antigen uptake into cells; use of the antigen-binding molecules for reducing the plasma concentration of a specific antigen; use of the modified FcRn-binding domain for increasing the total number of antigens to which a single antigen-binding molecule can bind before its degradation; use of the modified FcRn-binding domain for improving pharmacokinetics of an antigen-binding molecule; methods for decreasing the binding activity for a pre-existing anti-drug a

Abstract: A sidewalk information generation device includes a thinning unit configured to perform thinning processing for extracting, from image data indicating an area of a sidewalk, a centerline in a width direction of the area of the sidewalk, a segmentation unit configured to perform segmentation processing for dividing the centerline extracted by the thinning unit in a longitudinal direction to generate a plurality of lines, and a vectorization unit configured to convert each of the plurality of lines generated by the segmentation unit to vector data indicating a coordinate sequence of a plurality of line segments.

Abstract: A sidewalk network information generation device in an embodiment includes a sidewalk centerline data storage device configured to store sidewalk centerline data indicating a plurality of sidewalk centerlines, a detection unit configured to detect an end point and a corner point of each of the plurality of sidewalk centerlines from the sidewalk centerline data stored in the sidewalk centerline data storage unit, and a link information generation unit configured to select, from among the end points and the corner points of the plurality of sidewalk centerlines detected by the detection unit, first coordinates indicating an end point or a corner point of a first sidewalk centerline and second coordinates indicating an end point or a corner point of a second sidewalk centerline within a certain distance from the first coordinates, and generate link information for linking the plurality of sidewalk centerlines on the basis of the selected first and second coordinates.

Abstract: An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.

Abstract: An infectious disease prevention supporting device according to an embodiment of the present invention is an infectious disease prevention supporting device including a processor. The processor is configured to perform a detection process that detects a motion of a forearm or a wrist by a user, a proximity determination process that determines whether the user's hand is in proximity to a mucosa of the user's face based on the motion detected by the detection process for a predetermined period of time, and a warning generation process that generates a warning to suppress the proximity of the user's hand to the mucosa when it is determined by the proximity determination process that the user's hand is in proximity to the mucosa.

Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.

Abstract: An allocation search device includes: a first sample output unit that outputs, on the basis of past event occurrence data, a first main sample that may occur under a predetermined condition and a first auxiliary sample that may occur under a similar condition; an allocation plan creation unit that creates a plurality of allocation plans of resources for an occurring event; a first allocation evaluation unit that evaluates whether or not each of the plurality of allocation plans satisfies a predetermined evaluation criterion in a case where the first main sample and the first auxiliary sample are applied to each of the plurality of allocation plans; a second sample output unit that outputs, on the basis of latest event occurrence data, a future second main sample that may occur under the predetermined condition and a future second auxiliary sample that may occur under the similar condition; and a second allocation evaluation unit that, in a case where the second main sample and the second auxiliary sample are

Abstract: A display control device controls a display unit to display position information of an emergency vehicle, a predictive distribution of an occurrence point, and a risk level, the occurrence point representing a point at which a call for the emergency vehicle occurs, the risk level being determined depending on a time required for the emergency vehicle to arrive at the occurrence point after the call for the emergency vehicle occurs or a distance between the emergency vehicle and the occurrence point.

Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.

Abstract: A comparison unit 68 compares target data to be inferred with a learning data group that is data used for learning of the inference model, and determines that an inference result is uncertain when a comparison result does not satisfy a fixed criterion. A notification unit 70 notifies a user that the inference result is uncertain in addition to the inference result when the inference result is determined to be uncertain.

Abstract: The present inventors newly discovered that even if an antigen-binding molecule inhibits in vitro some of the physiological activities of an antigen having two or more physiological activities without inhibiting the remaining physiological activities, the molecule can promote elimination of the antigen from blood (from serum or plasma) and as a result reduce the physiological activities in vivo, when the antigen-binding molecule is conferred with the properties: (i) of binding to human FcRn under an acidic pH range condition; (ii) of binding under a neutral pH range condition to human Fc receptor stronger than native human IgG, and (iii) that its antigen-binding activity alters according to the ion concentration.

Abstract: A waypoint setting device sets a waypoint on the basis of a predictive distribution representing a demand prediction of occurrence points indicating positions from which a mobile object is called, position information indicating a position of a target mobile object that is a mobile object for which the waypoint is to be set, and destination information indicating information regarding a destination to which the target mobile object is to be moved. Then, the waypoint setting device outputs the set waypoint.

Abstract: The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc? receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.

Abstract: The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fc? receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.

Abstract: An objective of the present invention is to provide methods for facilitating antigen-binding molecule-mediated antigen uptake into cells, methods for facilitating the reduction of antigen concentration in plasma, methods for increasing the number of antigens to which a single antigen-binding molecule can bind, methods for improving pharmacokinetics of antigen-binding molecules, antigen-binding molecules improved for facilitated antigen uptake into cells, antigen-binding molecules capable of facilitating the reduction of antigen concentration in plasma, antigen-binding molecules capable of repeatedly binding to antigens, antigen-binding molecules with improved pharmacokinetics, pharmaceutical compositions comprising such an antigen-binding molecule, and methods for producing those described above.

Abstract: The present invention provides pharmaceutical compositions comprising second-generation molecules that are superior than TOCILIZUMAB, by altering the amino acid sequences of the variable and constant regions of TOCILIZUMAB, which is a humanized anti-IL-6 receptor IgG1 antibody, to enhance the antigen-neutralizing ability and increase the pharmacokinetics, so that the therapeutic effect is exerted with a less frequency of administration, and the immunogenicity, safety and physicochemical properties (stability and homogeneity) are improved. The present invention also provides methods for producing these pharmaceutical compositions. The present inventors have successfully generated second-generation molecules that are superior to TOCILIZUMAB by appropriately combining amino acid sequence alterations in the CDR domains, variable regions, and constant regions.

Abstract: The present invention provides antigen-binding molecules containing (i) an antigen-binding domain whose antigen-binding activity varies depending on ion concentration conditions, (ii) an Fc?R-binding domain having Fc? RIIb-selective binding activity, and (iii) an FcRn-binding domain having FcRn-binding activity under an acidic pH range condition, and methods of decreasing plasma antigen concentration as compared to before administering the molecule, which include the step of administering the molecule.

Abstract: The present inventors created antigen-binding molecules containing an antigen-binding domain and an Fc?-receptor-binding domain, wherein the molecules have human-FcRn-binding activity in an acidic pH range condition, the antigen-binding domain changes the antigen-binding activity of the antigen-binding molecules depending on the ion-concentration condition, and the Fc? receptor-binding domain has higher binding activity to the Fc? receptor in a neutral pH range condition than an Fc region of a native human IgG in which the sugar chain bound at position 297 (EU numbering) is a fucose-containing sugar chain.